ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
ctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLC	Neoplasm, Residual, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm	Active, not recruiting	Not stated	2026-08-31		NCT05198154

46 results · Page 1 of 2

Swipe the table sideways for more columns.

Organizations	Linked trials
Cancer Hospital of Guangxi Medical University	22
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	294
Changde Hospital, Xiangya School of Medicine, Central South University	3
Changsha Central Hospital	6
Changsha First Hospital	3
Changsha Third Hospital	3
Chenzhou NO. 1 people's Hospital	1
Fang Wu	2
First Affiliated Hospital of Kunming Medical University	31
First Affiliated Hospital of Xinjiang Medical University	42
First Affiliated Hospital Xi'an Jiaotong University	142
Fujian Cancer Hospital	114
Guizhou Provincial People's Hospital	26
Hengyang Central Hospital	4
Hunan Cancer Hospital	66
Hunan Provincial Hospital of Traditional Chinese Medicine	1
Hunan Provincial People's Hospital	23
Hunan Shaoyang Central Hospital	4
Hunan University of Medicine General Hospital	4
Inner Mongolia People's Hospital	11
Jiangsu Cancer Institute & Hospital	45
Liaoning Cancer Hospital & Institute	53
Loudi Central Hospital	8
Qinghai Province Fifth People's Hospital	5
Renmin Hospital of Wuhan University	73

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Oncology Department，Second Xiangya Hospital of Central South University	Changsha	China	2

Clinical trials